Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Pharmacokinetics
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacokinetics

1 evidence topic · 1 source

Pharmacokinetics: phase I study

“The half‐life of ivonescimab ranged from 5.0 to 7.3 days following single‐dose administration across all dose levels.” (opens the source at this quote in a new tab)
“steady state was achieved after 5 doses.” (opens the source at this quote in a new tab)